Valuation : COSCIENS Biopharma Inc.

Market Cap 5.35M 4.6M 4.33M 3.96M 7.4M 505M 7.42M 51.16M 19.85M 259M 20.08M 19.64M 835M P/E 2024
-0.45x
P/E 2025 -0.63x
Enterprise Value 190K 163K 154K 140K 262K 17.91M 263K 1.81M 704K 9.19M 712K 697K 29.61M EV / Sales 2024
-0.97x
EV / Sales 2025 0.19x
Free-Float
72.47%
Yield 2024 *
-
Yield 2025 -
1 day-1.33%
1 week+1.37%
Current month+1.37%
1 month+4.96%
3 months-3.65%
6 months+22.72%
Current year-13.15%
1 week 7.25
Extreme 7.25
7.5
1 month 7
Extreme 7
7.95
Current year 3.3
Extreme 3.299983
14.8
1 year 3.3
Extreme 3.299983
14.8
3 years 3.3
Extreme 3.299983
45.39
5 years 3.3
Extreme 3.299983
372
10 years 3.3
Extreme 3.299983
2,228.99
Date Insider Type Main position Quantity % Market Cap. Importance
8/4/26 A Option

Director

6,000 0.5653%
8/4/26 A Option

Chief Technology Officer

11,000 1.0364%
8/4/26 A Other

Chief Technology Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-1.33%+1.37%-28.50%-81.97% 5.33M
-2.54%-2.84%-1.77%+14.33% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
+0.53%-1.36%+16.87%+46.82% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.01%+0.50%+13.91%+31.83% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.96%+0.48%+62.66%+88.89% 27.5B
Weighted average by Cap. -1.03%+0.11%+89.42%+128.97%

Financials

2024 2025
Net sales 9.59M 8.25M 7.76M 7.09M 13.26M 905M 13.3M 91.72M 35.59M 464M 36M 35.21M 1.5B 7.5M 6.45M 6.07M 5.55M 10.37M 708M 10.4M 71.73M 27.84M 363M 28.16M 27.54M 1.17B
Net income -15.31M -13.17M -12.39M -11.32M -21.18M -1.45B -21.24M -146M -56.83M -742M -57.49M -56.23M -2.39B -10.36M -8.91M -8.39M -7.66M -14.33M -978M -14.37M -99.09M -38.45M -502M -38.9M -38.05M -1.62B
Net Debt -14.08M -12.12M -11.4M -10.42M -19.48M -1.33B -19.54M -135M -52.28M -682M -52.88M -51.73M -2.2B -5.16M -4.44M -4.18M -3.81M -7.14M -487M -7.16M -49.35M -19.15M -250M -19.37M -18.95M -805M
Logo COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Employees
28
Date Price Change Volume
03/09/26 CA$7.400 -1.33% 1,706
02/09/26 CA$7.500 +3.45% 100

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSCI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!